| Manufacturing Network Grant | Dr Brian Rudolph Shy | Open Manufacturing Network for Cell and Gene Therapies |
$1,999,933 |
| Foundation – Discovery Stage Research Projects | Tomasz Nowakowski | Neuroimmune interactions in the developing human brain |
$1,626,000 |
| Foundation – Discovery Stage Research Projects | Faranak Fattahi | hPSC-derived enteric ganglioids for cell therapy in gastrointestinal motility disorders |
$1,589,307 |
| Foundation – Discovery Stage Research Projects | Tien Peng | Ex vivo fate mapping of human lung stem cell plasticity in fibrotic disease |
$1,625,998 |
| Foundation – Discovery Stage Research Projects | Erik Ullian | Modeling Retinitis Pigmentosa using patient-derived human iPSC organoids |
$1,380,543 |
| Foundation – Discovery Stage Research Projects | Tomasz Nowakowski | Identifying roadblocks to neural stem cell transplantation into human tissues. |
$1,551,394 |
| Foundation – Discovery Stage Research Projects | Dr. Elizabeth Crouch | Harnessing vascular stem cells to grow and protect the human brain |
$1,391,998 |
| Foundation – Discovery Stage Research Projects | Yin Shen PhD | Understanding Chemotherapy-Induced Peripheral Neuropathy Mechanisms using CRISPRi and Chemical Screens in Human iPSC-Derived Sensory Neurons |
$1,621,913 |
| Foundation – Discovery Stage Research Projects | Dr. Robert Blelloch MD, PHD. | Development of universal off-the-shelf iPSC derived dendritic cells for use as patient specific anti-tumor vaccine |
$1,391,999 |
| Foundation – Discovery Stage Research Projects | Harold A. Chapman | Modulation of human alveolar stem cells to promote lung regeneration and avoid pulmonary fibrosis |
$1,626,001 |
| Research Training Grant | Dr. Robert Blelloch MD, PHD. | Scholars Research Training Program in Regenerative Medicine, Gene Therapy, and Stem Cell Research |
$5,373,742 |
| Clinical Trial Stage Projects | Dr. Michael Matthay MD | Mesenchymal Stromal Cells for ARDS (COVID positive and COVID negative) |
$701,049 |
| Cure Sickle Cell Initiative Clinical Trial Stage Projects | Mark C. Walters M.D. | Transplantation of CRISPR-CAS9 Corrected Hematopoietic Stem Cells (CRISPR_SCD001) in Patients with Severe Sickle Cell Disease |
$8,389,407 |
| Conference – The 2019 Alpha Stem Cell Clinic Annual Symposium | Mark C. Walters M.D. | 2019 Alpha Stem Cell Clinic Symposium – Mending Stem Cells: The Past, Present & Future Regenerative Medicine |
$60,000 |
| Alpha Stem Cell Clinics Network Expansion | Mark C. Walters M.D. | University of California, San Francisco (UCSF) Alpha Stem Cell Clinic (ASCC) |
$7,994,347 |
| Alpha Stem Cell Clinics Network Expansion | Mark C. Walters M.D. | University of California, San Francisco (UCSF) CIRM Alpha Stem Cell Clinic |
$5,087,847 |
| Quest – Discovery Stage Research Projects | Faranak Fattahi | Drug discovery for gastrointestinal motility disorders using hPSC-derived enteric ganglioids |
$1,954,367 |
| Quest – Discovery Stage Research Projects | Michael Wilson | A First-in-Class Treatment for Progressive Multifocal Leukoencephalopathy Via Multimodal Immune System Engineering |
$2,182,396 |
| Quest – Discovery Stage Research Projects | Brian Feeley | Matrix Assisted Cell Transplantation of Promyogenic Fibroadipogenic Progenitor (FAP) Stem Cells |
$1,179,478 |
| Quest – Discovery Stage Research Projects | Dr. Julie Deane Saba | Providing a cure for sphingosine phosphate lyase insufficiency syndrome (SPLIS) through adeno-associated viral mediated SGPL1 gene therapy |
$1,463,400 |
| Quest – Discovery Stage Research Projects | Dr Julia Carnevale | Generating deeper and more durable BCMA CAR T cell responses in Multiple Myeloma through non-viral knockin/knockout multiplexed genome engineering |
$1,463,368 |
| Quest – Discovery Stage Research Projects | Dr Marisa Medina | iPSCs as a screening tool to predict risk of nonalcoholic fatty liver disease |
$813,000 |
| Quest – Discovery Stage Research Projects | Dr. Hideho Okada | Non-viral reprogramming of the endogenous TCRα locus to direct stem memory T cells against shared neoantigens in malignant gliomas |
$900,000 |
| Quest – Discovery Stage Research Projects | Dr. Shuvo Roy | Silicon Nanopore Membrane encapsulated enriched-Beta Clusters for Type 1 Diabetes treatment |
$1,113,000 |
| Quest – Discovery Stage Research Projects | Dr. Holger F Willenbring | Preclinical development of AAV vector-mediated in vivo hepatic reprogramming of myofibroblasts as a therapy for liver fibrosis |
$1,638,389 |
| Quest – Discovery Stage Research Projects | Dr. Julie B Sneddon | Designing a cellular niche for transplantation of human embryonic stem cell-derived beta cells |
$2,006,076 |
| Quest – Discovery Stage Research Projects | Dr. Tejal Ashwin Desai | Thin Film Encapsulation Devices for Human Stem Cell derived Insulin Producing Cells |
$1,092,063 |
| Inception – Discovery Stage Research Projects | Semil P Choksi | Generation of human airway stem cells by direct transcriptional reprogramming for disease modeling and regeneration |
$238,408 |
| Inception – Discovery Stage Research Projects | Sonja Schrepfer | Hypo-immunogenic cardiac patches for myocardial regeneration |
$235,818 |
| Inception – Discovery Stage Research Projects | Dr. Holger F Willenbring | Generation of bile duct-competent transplantable human liver organoids |
$206,460 |
| Inception – Discovery Stage Research Projects | Andrew Stephen Brack | Examining the efficacy of GDF11 antibody as a rejuvenator of aged human muscle stem cell capacity and muscle repair . |
$180,000 |
| Diagnostic Translational Research Projects | Dr. Steven Mack PhD | Development of a Noninvasive Prenatal Test for Beta-Hemoglobinopathies for Earlier Stem Cell Therapeutic Interventions |
$633,014 |
| Therapeutic Translational Research Projects | Sarah Monica Knox | Neurogenic hydrogel stimulation of stem cells to regenerate radiation-damaged salivary glands |
$2,312,021 |
| Therapeutic Translational Research Projects | Arun P Wiita | CD72 nanoCARs for the treatment of refractory pediatric B-cell acute lymphoblastic leukemia |
$3,330,801 |
| Therapeutic Translational Research Projects | Dr. Hideho Okada | Development of novel synNotch CART cell therapy in patients with recurrent EGFRvIII+ glioblastoma |
$4,556,536 |
| Therapeutic Translational Research Projects | Dr. Hideho Okada | Development of novel synNotch CART cell therapy in patients with recurrent EGFRvIII+ glioblastoma |
$525,000 |
| Therapeutic Translational Research Projects | Dr. Karin Lindgren Gaensler | Developing engineered autologous leukemia vaccines to target residual leukemic stem cells |
$4,171,728 |
| Therapeutic Translational Research Projects | Mark C. Walters M.D. | Curing Sickle cell Disease with CRISPR-Cas9 genome editing |
$60,635 |
| SPARK | Katherine Nielsen | Stem Cell Summer Research Experiences |
$508,750 |
| SPARK | Katherine Nielsen | Developing High School Students’ Research Practices and Regenerative Medicine Knowledge through a Summer Intern Program |
$382,430 |
| Conference II | Professor Jeffrey Charles Lotz | 2023 Center for Dental, Oral, & Craniofacial Tissue & Organ Regeneration (C-DOCTOR) Annual Spring Conference |
$30,250 |
| Conference II | Rong Wang | 22nd International Vascular Biology Meeting |
$50,000 |
| Conference II | David H Rowitch | “Myelin Through the Ages: Evolution, Development, Degeneration and Disease” – 2018 Gordon Research Conference (GRC) and Gordon Research Seminar (GRS) |
$10,000 |
| Clinical Trial Stage Projects | Dr. Hideho Okada | Phase 1 Study of Autologous E-SYNC T Cells in Adult Participants with EGFRvIII+ Glioblastoma |
$10,927,618 |
| Clinical Trial Stage Projects | Steven G. Deeks | Anti-HIV duoCAR-T cell therapy for HIV infection |
$8,970,732 |
| Clinical Trial Stage Projects | Peter Stock | Pancreatic Islets and Parathyroid Gland Co-transplantation for Treatment of Diabetes in the Intra-Muscular Site: PARADIGM |
$11,083,012 |
| Clinical Trial Stage Projects | Mort Cowan | Gene Transfer for Artemis-Deficient Severe Combined Immunodeficiency Using a Lentiviral Vector to Transduce Autologous CD34 Hematopoietic Stem Cells |
$12,000,000 |
| Clinical Trial Stage Projects | Dr. Tippi C. Mackenzie MD | In Utero Hematopoietic Stem Cell Transplantation For The Treatment Of Fetuses With Alpha Thalassemia Major |
$9,350,000 |
| Late Stage Preclinical Projects | Thomas Martin | A 1XX-enhanced and fully non-viral BCMA CAR T cell therapy for Relapsed and Refractory Multiple Myeloma (UCCT-BCMA-1) |
$4,585,501 |
| Late Stage Preclinical Projects | Dr. Karin Lindgren Gaensler | Development of TriLeukeVax, an Engineered Autologous Leukemia Vaccine for Stimulating Cytolytic Immune Responses to Residual Leukemic Stem Cells |
$6,000,000 |
| Late Stage Preclinical Projects | Mark C. Walters M.D. | Curing Sickle cell Disease with CRISPR-Cas9 genome editing |
$2,242,805 |
| Late Stage Preclinical Projects | Dr. Krystof Bankiewicz | MRI Guided Delivery of Neural Progenitor Cells Secreting GDNF for the Treatment of Parkinson’s disease |
$5,757,078 |
| Late Stage Preclinical Projects | Dr Jennifer M Puck | Ex Vivo Transduction of the Human Artemis (DCLRE1C) cDNA by Lentiviral Vector AProArt into CD34+ Hematopoietic Cells for Artemis (ART)-Deficient Severe Combined Immunodeficiency (SCID) |
$4,268,865 |
| Tools and Technologies III | Dr. Andrew D. Leavitt MD | Small molecule tools and scale-up technologies to expand human umbilical cord blood stem and progenitor cells for clinical and research use |
$1,416,600 |
| Conference | Dr Diana Jean Laird | The 2014 Santa Cruz Developmental Biology Meeting |
$3,000 |
| Conference | Dr. Emmanuelle Passegue | CA-HSCI 1st Generation Stem Cell PI Meeting |
$20,000 |
| Conference | Dr. Ophir Klein MD, PhD | Stem Cells Craniofacial Development and Disease |
$4,500 |
| Conference | Dr. Arnold Kriegstein MD, PhD | UCSF Frontiers of Neural Stem Cells Symposium |
$35,000 |
| Conference | Dr. Brian Black | Weinstein Cardiovascular Development Conference |
$35,000 |
| Conference | Jason R. Rock | Tri-Institutional Stem Cell Retreat |
$3,500 |
| Conference | Dr. Tippi C. Mackenzie MD | In Utero Hematopoietic Stem Cell Transplantation and Maternal-Fetal Tolerance |
$17,526 |
| Conference | Jeffrey Rosenfeld | California ALS Research Summit 2014 |
$8,563 |
| Conference | Regis Kelly | The Science of Staying Younger Longer |
$6,500 |
| Conference | Dr. Susan J Fisher PhD | The Stem Cell Niche in Development and Disease |
$5,000 |
| Conference | Dr. Peter G. Stock | IPITA 2013 – 14th World Congress of the International Pancreas and Islet transplant Association |
$10,000 |
| Disease Team Planning | Professor Jeffrey Charles Lotz | A CIRM Disease Team for the Repair of Traumatically Injured and Arthritic Cartilage |
$33,172 |
| Disease Team Planning | Dr. Jeffrey A Bluestone | A CIRM Disease Team for the Treatment and Cure of Diabetes |
$55,000 |
| Major Facilities | Dr. A. Eugene Washington | UCSF CIRM Building |
$34,862,400 |
| Basic Biology V | Dr. Valerie Marie Weaver | Biophysical Determinants of Early Embryonic Stem Cell Fate Specification |
$1,186,500 |
| Basic Biology V | Dr. Mark S. Anderson | Generation of a functional thymus to induce immune tolerance to stem cell derivatives |
$1,191,000 |
| Patent Assistance Fund Awards | Karin Immergluck PhD | Patent Assistance Fund Proposal – UCSF |
$87,257 |
| Tissue Collection for Disease Modeling | Jacquelyn J Maher | iPSC-derived Hepatocytes as Platforms for Research in Viral Hepatitis and Non-alcoholic Steatohepatitis |
$791,680 |
| New Faculty Physician Scientist | Dr. Tippi C. Mackenzie MD | In Utero Embryonic Stem Cell Transplantation to Treat Congenital Anomalies |
$2,661,742 |
| New Faculty Physician Scientist | Dr. Ophir Klein MD, PhD | Stem cell therapy for inflammatory bowel disease |
$3,019,013 |
| New Faculty Physician Scientist | Jason Harris Pomerantz | Characterization of Human Skeletal Muscle Stem Cells for Clinical Application |
$2,959,014 |
| New Faculty Physician Scientist | Ann Capela Zovein | Human endothelial reprogramming for hematopoietic stem cell therapy. |
$2,197,683 |
| Creativity Awards | Katherine Nielsen | UCSF SEP High School Intern Program |
$168,947 |
| Basic Biology IV | Dr. Jeremy Reiter | Modeling disease in human embryonic stem cells using new genetic tools |
$1,387,800 |
| Basic Biology IV | Barbara Panning | Investigation of the role of O-GlcNAcylation in SOX2 function during reprogramming |
$1,260,037 |
| Basic Biology IV | Dr. Miguel Ramalho-Santos | Genetic dissection of human cellular reprogramming to pluripotency |
$1,184,883 |
| Early Translational III | Mort Cowan | Gene Correction of Autologous Hematopoietic Stem Cells in Artemis Deficient SCID |
$3,862,367 |
| Early Translational III | Dr. Holger F Willenbring | Generation of safe and therapeutically effective human induced hepatocyte-like cells |
$1,544,170 |
| Early Translational III | Dr. Arnold Kriegstein | Human ES cell-derived MGE inhibitory interneuron transplantation for spinal cord injury |
$1,623,251 |
| Training Grant I-1 | Dr. Susan J Fisher PhD | Training Grant I |
$2,868,145 |
| Research Training II | Dr. Susan J Fisher PhD | Training Program in Stem Cell Research at UCSF |
$7,814,027 |
| Basic Biology III | Jason Harris Pomerantz | Phenotypic Analysis of Human ES Cell-Derived Muscle Stem Cells |
$1,381,296 |
| Basic Biology III | Dr. John P Murnane Dr. | Genomic instability during culturing of human embryonic stem cells |
$1,070,919 |
| Tools and Technologies II | Dr Daniel A. Lim MD, PHD | Development and preclinical testing of new devices for cell transplantation to the brain. |
$1,795,891 |
| Early Translational II | Dr. Arturo Alvarez-Buylla | Inhibitory Nerve Cell Precursors: Dosing, Safety and Efficacy |
$1,564,016 |
| Early Translational II | Markus Muschen | Dual targeting of tyrosine kinase and BCL6 signaling for leukemia stem cell eradication |
$2,756,536 |
| Research Leadership | Redacted | Recapitulating development of the musculoskeletal axis in vitro with pluripotent cells |
$0 |
| Transplantation Immunology | Dr. Tippi C. Mackenzie MD | Maternal and Fetal Immune Responses to In Utero Hematopoietic Stem Cell Transplantation |
$1,230,869 |
| Transplantation Immunology | Dr. Jeffrey A Bluestone | Stem cell tolerance through the use of engineered antigen-specific regulatory T cells |
$1,152,768 |
| Transplantation Immunology | Dr. Mark S. Anderson | Stem cell differentiation to thymic epithelium for inducing tolerance to stem cells |
$1,314,089 |
| Shared Labs | Dr. Linda C. Giudice | The University of California San Francisco Shared Research and Teaching Laboratory: a Non-Federal Human Embryonic Stem Cell Resource for the Bay Area Community |
$2,144,758 |
| Shared Labs | Dr. Linda C. Giudice | The University of California San Francisco Shared Research and Teaching Laboratory: a Non-Federal Human Embryonic Stem Cell Resource for the Bay Area Community |
$3,289,649 |
| New Faculty II | Dr. Emmanuelle Passegue | Mechanisms Underlying the Responses of Normal and Cancer Stem Cells to Environmental and Therapeutic Insults |
$2,124,488 |
| New Faculty II | Dr. Ophir Klein MD, PhD | Laying the groundwork for building a tooth: analysis of dental epithelial stem cells |
$3,075,251 |
| New Faculty II | Dr. Robert Blelloch Dr. | Mechanisms of small RNA regulation in early embryonic development |
$2,790,695 |
| New Faculty II | Dr. Holger F Willenbring | Molecular dissection of adult liver regeneration to guide the generation of hepatocytes from pluripotent stem cells |
$2,832,008 |
| New Faculty II | Dr. Jeremy Reiter | High throughput modeling of human neurodegenerative diseases in embryonic stem cells |
$2,259,092 |
| New Cell Lines | Dr. Susan J Fisher PhD | Optimization of Human Embryonic Stem Cell Derivation Techniques and Production/Distribution of GMP-Grade Lines |
$1,383,419 |
| New Cell Lines | Dr. Miguel Ramalho-Santos | Somatic cell age and memory in the generation of iPS cells |
$1,307,201 |
| New Cell Lines | Dr. Long-cheng Li | Induction of pluripotent stem cells by small RNA-guided transcriptional activation |
$1,368,461 |
| Comprehensive Grant | Dr. Andrew D. Leavitt MD | Understanding hESC-based Hematopoiesis for Therapeutic Benefit |
$2,460,822 |
| Comprehensive Grant | Dr. Samuel Pleasure | Human stem cell derived oligodendrocytes for treatment of stroke and MS |
$2,459,235 |
| Comprehensive Grant | Dr. Harold S Bernstein Dr. | Modeling Myocardial Therapy with Human Embryonic Stem Cells |
$2,134,694 |
| Comprehensive Grant | Dr. Susan J Fisher PhD | Constructing a fate map of the human embryo |
$2,430,487 |
| Comprehensive Grant | Dr. Arnold Kriegstein MD, PhD | Derivation of Inhibitory Nerve Cells from Human Embryonic Stem Cells |
$2,410,874 |
| Comprehensive Grant | Dr. Randall James Lee | Embryonic Stem Cell-Derived Therapies Targeting Cardiac Ischemic Disease |
$2,424,353 |
| SEED Grant | Dr. Holger F Willenbring | Induction of pluripotency in fibroblasts by fusion with enucleated human embryonic stem cell syncytia |
$329,245 |
| SEED Grant | Dr. Thea D. Tlsty PhD | Role of the tumor suppressor gene, p16INK4a, in regulating stem cell phenotypes in embryonic stem cells and human epithelial cells. |
$614,784 |
| SEED Grant | Dr. Valerie Marie Weaver | Force, Dimensionality and Stem Cell Fate |
$529,762 |
| SEED Grant | Dr. Miguel Ramalho-Santos | Transcriptional Regulation of Human Embryonic Stem Cells |
$595,755 |
| SEED Grant | Dr. Heike E Daldrup-Link | Labeling of human embryonic stem cells with iron oxide nanoparticles and fluorescent dyes for a non-invasive cell depiction with MR imaging and optical imaging |
$240,214 |
| SEED Grant | Dr. Didier Y Stainier | Endodermal differentiation of human ES cells |
$611,027 |
| SEED Grant | Dr. Su Guo | Identifying small molecules that stimulate the differentiation of hESCs into dopamine-producing neurons |
$542,619 |
| SEED Grant | Dr. Linda C. Giudice | Human Embryonic Stem Cell Differentiation to Trophoblast: Basic Biology and Clinical Translation to Improve Human Fertility |
$614,784 |
| SEED Grant | Dr. Robert Blelloch Dr. | MicroRNA Regulation of Human Embryonic Stem Cell Self-Renewal and Differentiation |
$605,886 |
| Basic Biology II | Dr. John L Rubenstein | MGE Enhancers to Select for Interneuron Precursors Produced from Human ES Cells |
$1,387,800 |
| Disease Team Research I | Dr. Mitchel S Berger | Stem Cell-Mediated Oncocidal Gene Therapy of Glioblastoma (GBM) |
$6,214,914 |
